The critical role of monocytes in facilitating HUS was further validated by an intervening strategy in which depleting peripheral monocytes via CD14 neutralizing antibody, or blocking monocyte renal infiltration by CCL2 (MCP-1) inhibition, significantly attenuated kidney injury and dysfunction induced by LPS/Stx2 treatment. This evidence concerns the gene CD14 and hemolytic-uremic syndrome.